Eli Lilly SG&A Expenses 2010-2024 | LLY

Eli Lilly sg&a expenses for the twelve months ending December 31, 2024 were $8.594B, a 16.08% increase year-over-year.

  • Eli Lilly annual sg&a expenses for 2024 were $8.594B, a 16.08% increase from 2023.
  • Eli Lilly annual sg&a expenses for 2023 were $7.403B, a 14.95% increase from 2022.
  • Eli Lilly annual sg&a expenses for 2022 were $6.44B, a 0.14% increase from 2021.

Eli Lilly SG&A Expenses 2010-2024 | LLY

  • Eli Lilly annual sg&a expenses for 2024 were $8.594B, a 16.08% increase from 2023.
  • Eli Lilly annual sg&a expenses for 2023 were $7.403B, a 14.95% increase from 2022.
  • Eli Lilly annual sg&a expenses for 2022 were $6.44B, a 0.14% increase from 2021.
Related Stocks
Company NameMarket
Cap
Johnson & Johnson (JNJ)$380.1B
Novo Nordisk (NVO)$374.3B
AbbVie (ABBV)$348.4B
Roche Holding AG (RHHBY)$259.5B
Novartis AG (NVS)$218.5B
Merck (MRK)$216.5B
Pfizer (PFE)$146.7B
Sanofi (SNY)$136B
Bayer (BAYRY)$22B
Innoviva (INVA)$1.1B